| Formulary Chapter 4: Central nervous system - Full Chapter
|
| Chapter Links... |
 OCCG Guidelines: Primary Care Generalised Anxiety Disorder Guideline for Adults and Older Adults |
| Details... |
| 04.07.04.01 |
Treatment of the acute migraine attack |
|
|
|
|
|
|
| 04.07.04.01 |
Analgesics |
|
|
| 04.07.04.01 |
5HT1 agonists |
|
|
Sumatriptan
(Oral)
|
First Choice
|
First line triptan for treatment of acute migraine, in line with Migraine: Acute Therapy Guidelines (Adult).
NB. RADIS formulation is BLACK listed locally.
APCO November 2016.
|
|
|
Zolmitriptan
(Oral)
|
First Choice
|
First line triptan for treatment of acute migraine, in line with Migraine: Acute Therapy Guidelines (Adult).
APCO November 2016.
|
|
|
Naratriptan (Naramig®)
|
Second Choice
|
For treatment of acute migraine if unaccetable side effects with first-line triptans and for recurrent migraine, in line with Migraine: Acute Therapy Guidelines (Adult).
APCO November 2016.
|
|
|
Almotriptan (Almogran®)
|
Second Choice
|
For treatment of acute migraine if unaccetable side effects with first-line triptans, in line with Migraine: Acute Therapy Guidelines (Adult).
APCO November 2016.
|
|
|
Eletriptan (Relpax®)
|
Second Choice
|
For treatment of acute migraine if unaccetable side effects with first-line triptans and for recurrent migraine, in line with Migraine: Acute Therapy Guidelines (Adult).
APCO November 2016.
|
|
|
Frovatriptan
|
Formulary
|
For recurrent migraine in line with Migraine: Acute Therapy Guidelines (Adult).
APCO November 2016.
|
|
|
Sumatriptan (Imigran Subject® )
(6mg/0.5ml pre-filled injection)
|
 Restricted
|
For treatment of acute migraine if vomiting, in line with Migraine: Acute Therapy Guidelines (Adult).
NB: 3mg/0.5ml is blacklisted.
APCO November 2016.
|
|
|
Zolmitriptan (Zomig®)
(Nasal spray)
|
Restricted
|
For treatment of acute migraine if vomiting, in line with Migraine: Acute Therapy Guidelines (Adult).
APCO November 2016.
|
|
|
| 04.07.04.01 |
Ergot alkaloids |
|
|
| 04.07.04.01 |
Anti-emetics |
|
|
| 04.07.04.01 |
Other drugs for migrane |
|
|
| .... |
| Non Formulary Items |
Rizatriptan (Maxalt®)
|
Non Formulary
|
Not included in line with Migraine: Acute Therapy Guidelines (Adult). |
|
|
Sumatriptan
(3mg/0.5ml pre-filled injection)
|
Non Formulary
|
Not recommended for prescribing due to lack of evidence.
APCO September 2020. |
|
|
Sumatriptan (Imigran® Radis)
|
Non Formulary
|
Not recommended for use, refer to Migraine: Acute Therapy Guidelines (Adult).
APCO September 2015. |
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Red: Medicines which should only be prescribed in secondary care by a specialist. |
|
Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred. |
|
Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO). |
|
Green: Medicines which are suitable for initiation and ongoing prescribing within primary care. |
|
Brown: Medicines which should only be prescribed in restricted circumstances. |
|
Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety. |
|
not used |
|
|
|
